03/28/23 8:05 AMNasdaq : LHDX covid-19Lucira Health Announces U.S. Launch of First & Only At-Home Combination COVID-19 & Flu Test Amidst Sale ProcessCombination Test Also Secures Point-Of-Care Authorization in Australia Lab-quality results for both COVID-19 and Flu now available at home from one single test COVID-19 and Flu have similar symptoms but different treatments, requiring a fast, differential test to access time-sensitive prescriptionRHEA-AIvery positive
02/27/23 8:00 AMNasdaq : LHDX covid-19Lucira Health Announces FDA Authorization of First & Only At-Home Combination Covid-19 & Flu Test and Comments on Chapter 11 Bankruptcy FilingTest Delivers Lab-Quality Performance with Results in 30 Minutes or Less – The First At-Home Test to Ever Include Flu Lab-quality results for both COVID-19 and Flu now available at home from one single test COVID-19 and Flu have similar symptoms but different treatments, requiring a fast,RHEA-AIneutral
02/22/23 5:15 PMNasdaq : LHDX Lucira Health to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 ProcessLucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health,” “Lucira” or the “Company”), a medical technologyRHEA-AIneutral
01/05/23 9:00 AMNasdaq : LHDX partnershipSESAME PARTNERS WITH LUCIRA HEALTH AS OFFICIAL TELEHEALTH PROVIDER OF LAB-QUALITY TEST-TO-TREAT PROGRAMSesame , the company building a radically new healthcare systemRHEA-AIvery positive
01/04/23 7:00 AMNasdaq : LHDX covid-19Lucira Health Launches Lucira Connect, a Free Test-to-Treat Telehealth Service for Covid-19 or Flu in CanadaFor $98 CAD Canadians will receive a free telehealth appointment included with purchase of a test Lucira Connect provides lab-quality at-home test-users a telehealth visit at no additional cost, enabling Test-to-Treatment within hours for only the cost of the test, excluding prescription costs.RHEA-AIvery positive
01/03/23 7:00 AMNasdaq : LHDX covid-19Lucira Health Submits EUA for Over-The-Counter (OTC) Use of its COVID-19 & Flu TestLucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health" or "Lucira"), a medical technology company, announced that it submitted an Emergency Use Authorization application to the FDA for OTC use of its simple, at-home molecular COVID-19 & Flu test.RHEA-AIneutral
11/22/22 4:02 PMNasdaq : LHDX covid-19Lucira Health Announces FDA Authorization of Combination COVID-19 & Flu Test at Point-of-CarePCR-Quality Accuracy with Results in 30 Minutes or Less, Just in Time for Flu Season PCR Lab-quality NAAT/molecular test for both COVID-19 and flu from 1 shallow nasal swab Positive result as quickly as 11 minutes, negative result in 30 minutes, allowing diagnosis during patient visitRHEA-AIneutral
11/17/22 7:03 AMNasdaq : LHDX Lucira Health Announces National Launch of Lucira Connect Test-to-Treat ServiceDigital health service offers Lucira lab-quality at-home test users a telehealth visit at no additional cost, enabling Test-to-Treatment within hours for only $29, excluding prescription costs Lucira partners with Pfizer to increase awareness of the high risk factors for severe COVID-19 andRHEA-AIneutral
11/14/22 4:02 PMNasdaq : LHDX Lucira Health Announces Third Quarter 2022 Results and Provides Business UpdatesLucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financialRHEA-AIneutral
11/01/22 7:00 AMNasdaq : LHDX earningsLucira Health to Announce Third Quarter 2022 Financial ResultsLucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, and a digital health platform that will connectRHEA-AIneutral